Skip to main content
Aurobindo Pharma Ltd. logo

Aurobindo Pharma Ltd. — Investor Relations & Filings

Ticker · AUROPHARMA ISIN · INE406A01037 LEI · 335800G4T2A353RDGM23 BSE.NS Manufacturing
Open in API
Filings indexed 1,423 across all filing types
Latest filing 2026-05-15 Transaction in Own Shar…
Country IN India
Listing BSE.NS AUROPHARMA

About Aurobindo Pharma Ltd.

https://www.aurobindo.com/

Aurobindo Pharma Ltd. focuses on the development, manufacturing, and commercialization of generic formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning key therapeutic areas, including antibiotics, antiretrovirals, cardiovascular, central nervous system, gastroenterology, and anti-diabetics. With a strong emphasis on vertical integration, the organization manages a comprehensive supply chain from basic chemicals to finished dosage forms. It operates advanced research and development centers and manufacturing facilities that comply with international regulatory standards. The company serves a broad international market, providing cost-effective healthcare solutions through an extensive pipeline of Abbreviated New Drug Applications (ANDAs) and a robust distribution network.

Recent filings

Filing Released Lang Actions
Submission of certificate of extinguishment of 5423728 equity shares of Re.1/- of the Company bought back from the shareholders of the Company under Buyback Offer.
Transaction in Own Shares Classification · 90% confidence The document is an official stock exchange filing by Aurobindo Pharma Limited notifying the extinguishment of 54,23,728 equity shares bought back under SEBI Buyback Regulations, along with pre- and post-buyback share capital reconciliation and depository certificates. This is a report of the company’s own share repurchase and capital reduction. It is not a full financial report, dividend notice, voting result, or AGM material, but a transaction in own shares. Therefore, it fits the “Transaction in Own Shares” category.
2026-05-15 English
Closure of Buy Back
Transaction in Own Shares Classification · 95% confidence The document is a formal corporate announcement to stock exchanges regarding the extinguishment of 54,23,728 equity shares bought back by the company pursuant to SEBI Buy-Back Regulations, including reconciliation of share capital pre- and post-buyback. It is neither an earnings release nor a regulatory report attachment but a notification of the company’s own-share transaction (share repurchase extinguishment). This aligns with Transaction in Own Shares (Code: POS).
2026-05-15 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 82% confidence The document is an announcement under SEBI Listing Regulations scheduling an investor/analyst earnings call on May 22, 2026 to discuss the audited Q4FY26 and FY26 results. It contains no actual financial data or presentation, nor is it the transcript or the earnings release itself, but rather a regulatory notice of a conference call. This does not fit specific categories like ER (no key financials disclosed), CT (no transcript), IP (no investor presentation provided), or any other detailed report type. Hence it falls under the general regulatory announcement category.
2026-05-14 English
Intimation of schedule of Earnings Call to be held on May 22, 2026 at 8:30 AM (IST) on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2026.
Regulatory Filings Classification · 86% confidence The document is an announcement pursuant to Reg 30 of SEBI LODR notifying stock exchanges and investors of the schedule for the Q4FY26 earnings conference call (an invite/notice), but it does not contain any financial results, transcript, or presentation details itself. It is not a full earnings release (no financial highlights), not a transcript, nor is it a report itself. It fits the general regulatory announcement category for miscellaneous filings. Therefore, it is classified as a Regulatory Filing (RNS).
2026-05-14 English
Aurobindo Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve the Standalone & Consolidated ....
Board/Management Information Classification · 95% confidence The document is an intimation to stock exchanges under SEBI LODR Regulation 29 notifying a forthcoming Board of Directors meeting to consider and approve quarterly/annual audited results. It does not contain the results themselves but announces the board meeting, fitting the definition of a Board/Management Information filing.
2026-05-12 English
Submission of copy of post buyback public advertisement pertaining to buyback of shares of the Company.
Regulatory Filings
2026-05-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.